Epizyme, Inc. (NASDAQ:EPZM) was downgraded by equities researchers at ValuEngine from a “hold” rating to a “sell” rating in a report released on Monday, November 6th.
EPZM has been the subject of a number of other reports. BidaskClub downgraded Epizyme from a “sell” rating to a “strong sell” rating in a report on Friday, July 28th. Jefferies Group LLC began coverage on Epizyme in a report on Wednesday, September 20th. They issued a “buy” rating and a $23.00 price target for the company. Cann reissued a “buy” rating and issued a $26.00 price target on shares of Epizyme in a report on Thursday, November 2nd. Royal Bank Of Canada set a $20.00 price target on Epizyme and gave the company a “buy” rating in a report on Saturday, August 5th. Finally, Zacks Investment Research raised Epizyme from a “hold” rating to a “buy” rating and set a $16.00 price target for the company in a report on Tuesday, July 18th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $22.67.
Epizyme (NASDAQ:EPZM) traded down $0.25 during trading on Monday, hitting $12.65. The company had a trading volume of 223,975 shares, compared to its average volume of 513,011. Epizyme has a 12-month low of $9.30 and a 12-month high of $20.45.
Epizyme (NASDAQ:EPZM) last released its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.63) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.65) by $0.02. analysts expect that Epizyme will post -2.23 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This story was published by BBNS and is the sole property of of BBNS. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://baseballnewssource.com/markets/epizyme-inc-epzm-cut-to-sell-at-valuengine/1762368.html.
In other news, Director David M. Mott purchased 200,000 shares of the company’s stock in a transaction that occurred on Monday, September 18th. The stock was purchased at an average cost of $15.25 per share, for a total transaction of $3,050,000.00. Following the completion of the transaction, the director now owns 6,000 shares of the company’s stock, valued at $91,500. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Peter Tai-Ching Ho sold 15,000 shares of the business’s stock in a transaction that occurred on Thursday, August 24th. The stock was sold at an average price of $15.68, for a total value of $235,200.00. Following the sale, the insider now owns 22,228 shares of the company’s stock, valued at $348,535.04. The disclosure for this sale can be found here. Insiders have sold 45,000 shares of company stock valued at $733,950 over the last quarter. 25.20% of the stock is owned by company insiders.
Several institutional investors and hedge funds have recently modified their holdings of EPZM. Point72 Asset Management L.P. purchased a new stake in Epizyme in the 3rd quarter valued at $17,591,000. Palo Alto Investors LLC grew its holdings in Epizyme by 18.9% in the 2nd quarter. Palo Alto Investors LLC now owns 5,698,296 shares of the biopharmaceutical company’s stock valued at $86,044,000 after buying an additional 907,245 shares in the last quarter. State Street Corp grew its holdings in Epizyme by 59.6% in the 2nd quarter. State Street Corp now owns 1,764,450 shares of the biopharmaceutical company’s stock valued at $26,644,000 after buying an additional 658,727 shares in the last quarter. Lord Abbett & CO. LLC purchased a new stake in Epizyme in the 2nd quarter valued at $9,726,000. Finally, Bain Capital Public Equity Management LLC purchased a new stake in Epizyme in the 2nd quarter valued at $4,331,000. Hedge funds and other institutional investors own 70.95% of the company’s stock.
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with our FREE daily email newsletter.